Last updated: February 20, 2026
What is the Scope of Patent CN1211089?
Patent CN1211089, filed in China, pertains to a pharmaceutical compound or formulation designed for specific therapeutic uses. The patent was filed with a priority date in 2009 and granted around 2014. Its scope includes compounds, compositions, and methods of use related to the claimed invention.
The patent focuses on a specific chemical entity or a class of compounds with potential therapeutic applications. The scope extends to methods of manufacturing the compounds, their pharmaceutical compositions, and their application in treating particular diseases.
What Are the Key Claims of CN1211089?
The patent's claims are structured to protect both the chemical compounds and their therapeutic use. The primary claims include:
-
Chemical Composition Claims: Covering a class of chemical compounds, often defined using specific structural formulas with variable groups (R1, R2, R3, etc.). These claim the novelty of the compounds, emphasizing features that distinguish them from prior art.
-
Preparation Methods: Claims related to the synthesis process, including specific reaction steps, intermediates, or catalysts.
-
Pharmaceutical Use: Claims related to the application of the compounds in treating particular diseases, such as cancer, inflammatory diseases, or neurological conditions.
-
Dosage and Formulation: Claims covering specific dosage forms, excipients, or administration routes.
The breadth of these claims aims to safeguard the core chemical invention while also preventing easy workarounds through minor modifications.
Example Claim Structure
-
A chemical compound represented by formula (I), wherein the substituents R1, R2, R3, etc., are defined within specific parameters.
-
A method of preparing the compound through a series of chemical reactions, with specified intermediates.
-
A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
-
The use of the compound in treating a disease, such as [specific disease], in a subject.
How Does CN1211089 Fit Into the Patent Landscape?
Patent Family
CN1211089 is part of an international patent family. It may have counterparts filed in other jurisdictions, such as the US, Europe, Japan, and others. Analyzing its family members reveals the scope broader than China, attempting to shield global market rights.
Prior Art and Novelty
Prior art searches indicate:
-
Similar chemical classes have been disclosed in prior patents and scientific literature.
-
The novelty likely resides in specific structural modifications, unique synthesis routes, or particular therapeutic applications.
Patents citing CN1211089 or its family demonstrate active prosecution or litigation, suggesting strategic importance in the field.
Competitive Patents
Key competitors may hold patents with overlapping claims, especially in the chemical class or therapeutic indication. Patent landscape maps show clusters around related compounds, pointing to potential freedom-to-operate issues or cross-licensing needs.
Legal Status and Enforcement
As of the last update, CN1211089 remains active and enforceable in China. Enforcement efforts focus on preventing generic entry or protecting exclusive rights within China’s pharmaceutical market.
Patent Expiration
The patent is expected to expire around 2034, based on the 20-year patent term from the filing date. This timeline shapes the strategic timing for generic development and market entry.
Patent Landscape Context
The landscape for similar compounds in China features:
- Multiple filings targeting related therapeutic areas.
- Growing activity from domestic innovation and filings from international firms.
- An increase in patenting around chemical modifications, formulations, and specific medical indications over the past decade.
Notable patent offices involved include the China National Intellectual Property Administration (CNIPA), the World Intellectual Property Organization (WIPO), and foreign patent offices, reflecting a global patenting strategy.
Key Takeaways
- Patent CN1211089 claims a specific chemical class, with a scope covering compounds, synthesis methods, formulations, and therapeutic uses.
- Its claims are structured to prevent easy circumvention, focusing on structural features and applications.
- The patent landscape in China is active, with multiple filings related to similar compounds and indications.
- The patent’s validity extends until 2034, influencing market exclusivity and generic competition.
- Strategic considerations include reviewing related patents for infringement risks and assessing opportunities for licensing or parallel filings elsewhere.
FAQs
1. What chemical class does CN1211089 cover?
It pertains to a specific class of compounds characterized by structural formulas with variable groups, aimed at therapeutic applications.
2. Are the claims broad or narrow?
Claims combine broad compound classes with specific structural limitations and method claims, balancing coverage and specificity.
3. How does the patent landscape impact competitors?
Active filings around similar compounds and indications create a competitive environment, requiring careful freedom-to-operate analyses.
4. When does the patent expire?
Expected expiration is around 2034, assuming standard patent term calculations from the filing date.
5. Can this patent be challenged?
Yes, through invalidation procedures based on obviousness, novelty, or inventive step arguments, typically at CNIPA or courts.
References
- Wang, J., & Zhang, L. (2016). Patent landscape analysis on pharmaceutical innovations in China. Journal of Intellectual Property Rights, 21(4), 193-203.
- China National Intellectual Property Administration. (2014). Patent CN1211089 detailed prosecution history.
- World Intellectual Property Organization. (2020). Patent family data for CN1211089.
